Researchers evaluated the safety and efficacy of several antifungal agents for the treatment of invasive candidiasis infection.
Researchers conducted a study that assessed the rate of chronic pulmonary aspergillosis recurrence among patients who received oral itraconazole for 6 vs 12 months.
In this meta-analysis, researchers assessed the safety and efficacy of fluconazole compared with alternative antifungal agents for the treatment of esophageal candidiasis.
The phase 3 CANDLE study compared the efficacy and safety of ibrexafungerp to placebo in 260 female patients 12 years of age and older with rVVC.
Researchers conducted a study that assessed the rate of 90-day all-cause crude mortality vs attributable mortality among patients with candida bloodstream infections.
Researchers conducted a study to determine whether gardening activities are associated with an increased risk for exposure to triazole-resistant Asperigillus fumigatus fungal spores.
Investigators conducted a study to determine the effects of quinine hydrochloride in combination with antimicrobial blue light therapy in patients with cutaneous mold infection.
Investigators conducted a study to determine outcomes following early de-escalation to fluconazole following echinocandin empirical treatment in patients with fluconazole-susceptible candidemia.
Investigators analyzed data collected over more than 70 years to estimate the annual global incidence of this severe corneal infection.
The FDA has accepted for filing and granted Priority Review to the NDA for ibrexafungerp (SCY-078; Scynexis) for the treatment of vulvovaginal candidiasis.
Investigators summarized the evidence on the efficacy and adverse effects of antifungal agents in patients with hematological disease or undergoing hematopoietic stem cell transplantation.
Using FAERS, study researchers identified reported cases of tuberculosis and atypical mycobacterial infection in patients who received ICIs.
Critically ill patients hospitalized with COVID-19 — particularly those who develop ARDS — may also experience an opportunistic aspergillosis superinfection.
A novel study used network meta-analysis to compare pulse and continuous systemic therapies for toenail onychomycosis.
Fresenius Kabi announced the launch of Micafungin for Injection, a generic version of Mycamine (micafungin for injection; Astellas Pharma).
Adults with candidemia and persistently negative (1,3)-β-D-glucan tests present with a better prognosis than comparative groups.
The FDA has granted Fast Track designation to PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma.
The Centers for Disease Control and Prevention (CDC) summarized investigations into 3 cases of pan-resistant Candida auris infections in New York.
The FDA has approved the sNDA for Mycamine for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients aged <4 months.
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.